Having trouble accessing articles? Reset your cache.

Aluda: targeting the fundamentals

Aluda begins to unveil pipeline, starting with first-in-class anti-VIM program for fibrosis

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications.

CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years at Genentech Inc. with the goal of discovering novel compounds that target fundamental processes associated with pathogenesis. Chen also co-founded Natrogen Therapeutics Intl. Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired.

Aluda has thus far

Read the full 694 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE